BTG plc (BTG) Receives GBX 676.25 Consensus Target Price from Brokerages

Shares of BTG plc (LON:BTG) have received a consensus rating of “Hold” from the seven brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is GBX 676.25 ($8.81).

BTG has been the subject of several research analyst reports. Peel Hunt reiterated a “hold” rating on shares of BTG in a research report on Wednesday, July 18th. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 650 ($8.47) price objective on shares of BTG in a report on Tuesday, August 21st. Numis Securities restated a “buy” rating and issued a GBX 840 ($10.94) price objective on shares of BTG in a report on Tuesday, June 5th. Shore Capital restated a “buy” rating on shares of BTG in a report on Friday, September 7th. Finally, Deutsche Bank restated a “hold” rating on shares of BTG in a report on Wednesday, June 13th.

BTG stock traded down GBX 12.50 ($0.16) during mid-day trading on Wednesday, hitting GBX 546 ($7.11). 450,485 shares of the company traded hands, compared to its average volume of 582,586. BTG has a one year low of GBX 559.82 ($7.29) and a one year high of GBX 784 ($10.21).

In other BTG news, insider Dame Pamela Louise Makin sold 73,410 shares of the business’s stock in a transaction on Tuesday, July 17th. The shares were sold at an average price of GBX 488 ($6.36), for a total transaction of £358,240.80 ($466,641.66). Also, insider Anne Thorburn acquired 15,000 shares of BTG stock in a transaction on Monday, July 23rd. The shares were bought at an average cost of GBX 500 ($6.51) per share, for a total transaction of £75,000 ($97,694.41).

BTG Company Profile

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.

Featured Story: Trading Strategy Methods for Individual Investors

Analyst Recommendations for BTG (LON:BTG)

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply